Keymeulen B, van Maurik A, Inman D, Oliveira J, et al. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia 2020 Nov 4. pii: 10.1007/s00125-020-05317.
PMID: 33145642